ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in…
The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting…